Tumour mutation burden >10 Muts/Mb on liquid biopsyMSI-HighPD1/PDL1/CTLA4 amplificationMLH1/MSH2/MSH6/PMS2POLD1 & POLE mutation or LOHexcept lung or urothelial or head and neck tumours. This evidence concerns the gene POLE and neoplasm.